5 ′ -AMP-activated protein kinase activation). In conclusion, we propose that metabolic imaging with FDG PET may provide a novel approach to guide the treatment of patients with hypertension-induced LVH. 
tabolism in the pressure-overloaded heart precede the development of LVH and impaired cardiac function [11, 12] and that targeting these metabolic changes may thus prevent the development of LVH and HF in the pressureoverloaded heart [13] [14] [15] . Additionally accurate metabolic imaging is able to identify changes in the myocardial substrate metabolism before and during the development of LVH and may be used to monitor therapeutic interventions to prevent LVH [16] [17] [18] [19] . Specifically, 2-deoxy-2-[
18 F]fluoro-D -glucose (FDG) is used to trace the dysregulated glucose metabolism. This is analogous to the cancer cell metabolism where increased FDG retention heralds cell growth and proliferation [20] .
The aim of this review is to summarize the knowledge derived from our work [11, 12] in support of the hypothesis that metabolic remodeling associated with increased growth signaling and functional changes precedes structural left ventricular remodeling induced by sustained pressure overload. We also discuss the role of pharmacological interventions targeting metabolic intermediates to prevent the progression to LVH and HF in the setting of pressure overload.
In vivo Characterization of Glucose Metabolism Changes in the Pressure-Overloaded Heart Using Serial FDG Positron Emission Tomography Imaging

FDG Positron Emission Tomography Imaging of the Mouse Heart during Induction of Pressure Overload
Noninvasive positron emission tomography (PET) imaging is used to identify metabolic substrate utilization [19] . However, myocardial glucose uptake rate estimates have been inaccurate in mouse hearts due to partial volume effects and spillover of radioactivity from the myocardium into the left ventricular blood pool and vice versa. In our novel quantitative method, blood input function with spillover and partial volume coefficients and metabolic rate constants in a compartment model are simultaneously estimated from attenuation-corrected, gated and dynamic high-resolution FDG PET images of mouse hearts in vivo [11, 21] . In conjunction with magnetic resonance imaging (MRI), used for measuring cardiac structure and function, we tested the hypothesis in vivo that early metabolic remodeling, recognized by increased myocardial FDG uptake, precedes structural left ventricular remodeling and decrease in cardiac function in a mouse model of transverse aortic constriction (TAC)-induced pressure overload LVH [11, 12] . In mice subjected to TAC surgery, there is a continuous increase in FDG uptake from the first day up to 4 weeks after surgery, whereas sham-operated animals show no change in FDG uptake over the same period ( fig. 1 a, b) . However, 1 day after TAC, when myocardial FDG uptake was significantly increased, there were no appreciable changes in the ratio of heart weight to body weight and in enddiastolic wall thickness, as measured using MRI. Significant decreases in the ejection fraction assessed by MRI, however, followed the metabolic changes [12] . In addition, there was a significant increase in glucose 6-phospate (G6P) levels 1 day after TAC in harvested hearts, and the increase was more pronounced 2 weeks after TAC ( fig. 1 c) . In order to unravel the molecular mechanisms leading to the structural changes observed in TAC mice, we investigated the participation of the mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) in the model of TAC-induced LVH [22] . mTORC1 is a major regulator of myocardial protein synthesis located downstream of the phosphatidylinositol-3 kinase signaling pathway and is a major driver of cardiac hypertrophy [23] . Already on day 1 after TAC, the mTORC1 targets p70S6 kinase and 4E-binding protein 1 were activated and remained so for 2 weeks ( fig. 1 d) . Thus, significant metabolic and cell signaling changes are present 1 day after TAC surgery and precede significant structural changes.
In vivo FDG PET during Pharmacologic Intervention
Metabolic imaging of the heart has been used to evaluate the response to therapeutic interventions. Studies using 31 P magnetic resonance spectroscopy show that decreased cardiac phosphocreatine/adenosine triphosphate ratios in failing hearts of patients with dilated cardiomyopathy increase and normalize in response to β-blocker therapy [24, 25] . Metabolic changes are also accompanied by an improved cardiac efficiency in patients with left ventricular dysfunction [26] . Measurements, such as percent glucose uptake with FDG PET, have also been used to evaluate the beneficial effect of β-blocker treatment in patients with dilated cardiomyopathy [27] . Using a 3-compartment kinetic model, we measured rates of myocardial FDG uptake (K i ) and regional glucose metabolic utilization in TAC mice treated with propranolol. Myocardial FDG uptake rates increased over a period of 7 days in TAC mice together with a reduction in cardiac function as compared to shams. Treatment with propranolol attenuated myocardial FDG uptake and simultaneously improved the cardiac function ( fig. 2 a-c) . Since rate of myocardial glucose utilization (rMGU) in TAC mice does not increase linearly with FDG uptake rates, but rather increases at a much slower rate, a mismatch of 29% between FDG uptake and rMGU results [11] . Note that this mismatch correlates with a significant myocardial G6P accumulation observed as early as 1 day after TAC ( fig. 1 c) . Early treatment with propranolol prevents the drastic increase in myocardial FDG uptake in the hearts of TAC mice, reduces the mismatch between FDG uptake and rMGU and preserves the left ventricular ejection fraction ( fig. 2 b, c) [11] . Thus, in vivo FDG PET studies are able to identify changes in myocardial glucose metabolism as a possible readout for cardiac efficiency.
In vivo FDG PET in Other Animal Models of LVH
The TAC mouse model lacks key features of the human disease, most importantly the slow progressive development of pressure overload. This makes it impossible to identify a window for aggressive therapeutic strategies that could be readily translated to clinical practice. The spontaneously hypertensive rat and the Dahl salt-sensitive rat are widely used models to study the transition from stable compensated LVH to systolic HF [28] [29] [30] [31] . Recent PET imaging studies in vivo by Hernandez et al. [32] in the spontaneously hypertensive rat heart over a period of 20 months observed significant increases in myocardial glucose and fatty acid utilization at both early and late stages, and these precede mechanical changes during LVH progression. Studies in the Dahl salt-sensitive rat model ex vivo [31] also revealed increased glucose uptake early in the progression from LVH to HF, but in contrast to Hernandez et al. [32] a late decrease in fatty acid metabolism was observed. Although evidence supporting an increase in glucose metabolism preceding LVH and HF is observed in both genetic and TAC-induced LVH animal models, there is no clear consensus yet on the changes and/or role of the fatty acid metabolism in the stressed heart in vivo. This is mainly due to the lack of adequate compartment models to noninvasively quantify the myocardial fatty acid metabolism that complements the conventional graphical Patlak analysis [32] .
Probing for Mechanisms ex vivo
G6P and mTOR Activation
We have previously shown that the uptake of FDG by the isolated working rat heart is linear with alterations in substrate supply and workload [33] . The in vivo FDG PET studies and the metabolic analysis on the harvested TAC hearts indicate a possible role of glucose-mediated mTOR activation in the pressure-overloaded mouse heart. To further elucidate the underlying mechanism, rates of glucose uptake and oxidation were simultaneously quantitated in ex vivo glucose-perfused isolated working rat hearts by Sen et al. [12] . At normal workload, the rates of glucose uptake matched the rates of glucose oxidation. However, when the workload was increased, the rates of glucose exceeded the rates of glucose oxidation, and G6P accumulated. In hearts from rats pretreated with rapamycin, the mismatch between glucose uptake and oxidation disappeared, as did the accumulation of G6P [12] ( fig. 3 a-c) . Because mTOR activation was associated with a mismatch between glucose uptake and oxidation, we further investigated whether G6P is a signal for mTOR activation when the heart workload is increased. For this Rate of myocardial FDG uptake and cardiac function in mouse heart in vivo subjected to TAC surgery without and with propranolol treatment over a period of 7 days. * p < 0.05 versus baseline, TAC treated with propranolol and sham groups. a End-diastolic transverse PET images for sham, TAC and TAC mice treated with propranolol at baseline and at day 1 and day 7 after surgery. b Measured K i (ml/g/min). c Ejection fraction measured using high-resolution gated PET images. Modified and reproduced with permission from the Journal of Nuclear Medicine [11] . purpose, 2 groups of hearts were perfused with either 1 of 2 glucose analogues, 3-O-methylglucose or 2-deoxyglucose. 3-O-methylglucose is transported into the cell cytoplasm but not phosphorylated, whereas 2-deoxyglucose is phosphorylated to 2-deoxyglucose-6-phosphate but not metabolized further (with the exception of cycling in and out of glycogen). Of the 2 analogues, only 2-deoxyglucose increased the phosphorylation of mTOR and its downstream targets in hearts perfused at a high workload ( fig. 3 d) . In vitro studies in cardiomyocytes suggest that hexokinase-II binds and inhibits mTORC1 during glucose deprivation. An increase in intracellular glucose concentration results in hexokinase-II mTORC1 unbinding and subsequent activation of mTORC1 [34] . Collectively, these experiments provide strong evidence that intracellular G6P levels are associated with mTOR activation in hearts subjected to increased workload. This mechanism of glucotoxic remodeling in pressure overload-induced cardiac dysfunction differs from previously described glucoprotective remodeling in the hibernating myocardium [35] and probably relates to enhanced glycogen metabolism in the latter [36] [37] [38] [39] .
G6P-Mediated mTOR Activation and 5 ′ -AMP-Activated Protein Kinase Downregulation
The enzyme 5 ′ -AMP-activated protein kinase (AMPK) regulates the substrate metabolism in the heart. Saha et al. [40] observed glucose-induced protein synthesis with downregulation of AMPK in the rat skeletal muscle. Similarly, we observed that rat hearts perfused with glucose at a high workload showed a decrease in the phosphorylation of AMPK and its downstream targets acetyl-CoA carboxylase and tuberin. These changes were prevented by pretreatment with rapamycin [12] ( fig. 4 a) . To determine the functional consequences of AMPK activation, hearts from rats pretreat- Fig. 3 . In response to a high workload, the rates of glucose uptake exceed the rates of glucose oxidation, G6P accumulates and mTOR is activated. Rates of glucose uptake and oxidation in glucose-perfused rat hearts at a high workload pretreated with vehicle ( a ) and rapamycin ( b ). Data shown are means ± SEM; n = 5-6 per group. n.s. = Not significant. * p = 0.07 with the Mann-Whitney rank sum test. c G6P levels in freeze-clamped rat hearts pretreated with vehicle or rapamycin. d Representative Western blots of mTOR activation in rat hearts perfused with glucose or glucose analogues 2-deoxyglucose (2DG), or 3-O-methylglucose (3OMG) at a normal and high workload. Modified and reproduced with permission from the Journal of American Heart Association [12] . 216 ed with metformin in vivo for 7 days were also perfused with glucose at a high workload. Metformin pretreatment resulted in a tight coupling of glucose uptake and oxidation, reduced G6P levels and increased cardiac power ( fig. 4 b-e).
mTOR Activation and Endoplasmic Reticulum Stress
Sustained mTOR activation results in protein synthesis unmatched by the folding capacity of the endoplasmic reticulum (ER) and induces ER stress [41] . Sen et al. [12] examined the possibility that sustained mTOR activation by G6P results in the induction of ER stress which may be responsible for the decline in cardiac power in hearts perfused at a high workload. Protein levels of GRP78, an ER chaperone protein, increased in hearts perfused with glucose at a high workload. The increase in GRP78 protein levels was not observed in hearts from animals pretreated with rapamycin or metformin ( fig. 5 a) . Also, an ER 'stress relieving' agent, the histone deacetylase inhibitor 4-phenylbutyrate, reduced the protein level of GRP78 ( fig. 5 a) and improved cardiac power ( fig. 5 b) .
General Considerations
Based on the literature discussed, we propose that dysregulation of the glucose metabolism is a prominent feature of the maladapted failing heart. Furthermore, we propose that metabolic changes precede and trigger structural and functional remodeling of the pressureoverloaded heart ( fig. 6 ). The glucometabolic footprint of the stressed heart manifests as follows:
(1) During acute pressure overload and inotropic stimulation [6] , rates of glucose uptake and oxidation are increased. It is not yet completely clear how this relates to left ventricular function during pressure overload LVH. Studies using single photon emission computed tomography imaging and PET have already demonstrated that the metabolic switch can be measured both in small animals and in human beings [42] . However, serial studies on the temporal relationship between glucose uptake and cardiac structure and function in mice in vivo using PET have thus far never been done. As demonstrated earlier [21] , a model-corrected blood input function applied to an image-derived blood input function obtained from high-resolution gated images [43] with less severe spillover and partial volume effects is quantitative and also repetitive as compared to that obtained from low-resolution ungated images [44] . Applying improved quantitative methods, we found that an increase in the glucose metabolism in the form of an increased FDG uptake precedes and possibly triggers the functional and structural remodeling of the heart in LVH in mice in vivo [12] . We also observed that early treatment with propranolol attenuated myocardial glucose uptake and rescued cardiac function in vivo [11] .
The attenuation of increased glucose uptake and the improved contractile function early in the course of treatment with propranolol suggests that an early detection of metabolic remodeling may offer a therapeutic opportunity to prevent the onset of severe contractile dysfunction. Thus, metabolic imaging with FDG PET may guide the treatment of patients with hypertension-induced LVH and improve clinical outcomes. This conclusion differs from FDG PET studies of patients with advanced cardiomyopathy [45, 46] , possibly for the following reasons: the subjects already had contractile dysfunction, hence beyond the mere correlation, it was impossible to establish a timeline or causality as we did with our studies. Furthermore, Taylor et al. [46] based the expected FDG uptake on findings observed by other investigators. Therefore, the difference observed between healthy individuals and the study group may lie in the protocol used, since graphical Patlak analysis without considering the confounding effects of partial volume and spillover and variability in the lumped constant used for the fatty acid and glucose tracers may limit the accuracy of this method. Furthermore, most of the patients included in their study had ischemic cardiomyopathy; hence, measurements in areas of the nonviable myocardium could falsely lower FDG uptake readings. Also, the patients were treated with angiotensin-converting enzyme inhibitors and digoxin, which may have further compromised myocardial metabolism. (2) Although it is known that mTOR signaling is responsible for cardiac growth in hypertrophy [23] , the role of G6P-mediated mTOR activation in cardiac dysfunction is a recent observation [47] . The findings in the working rat heart ex vivo demonstrate that acute increases in workload require the presence of glucose to activate mTOR, suggesting that 'load-induced' hypertrophic signaling through mTOR is substrate specific. More specifically, mTOR is activated by the metabolic signal G6P, which may induce hexokinase-II release from mTORC1.
(3) G6P accumulation, most likely via sustained mTOR activation, induces ER stress, elicits the unfolded protein response, and impairs contractile function. Pretreatment with rapamycin, metformin or PBA relieves ER stress, thereby rescuing the cardiac function in glucose-perfused rat hearts under a high workload ex vivo.
(4) Pharmacological interventions that prevent G6P accumulation and mTORC1 activation result in the restoration of cardiac power and decrease the progression of LVH. Propranolol treatment improves cardiac function in mice subjected to TAC, most likely by attenuating glu- Fig. 6 . Proposed mechanism by which metabolic remodeling precedes and triggers structural and functional remodeling in the heart. Sustained pressure overload leads to increased glucose metabolism. However, a mismatch between glucose uptake and oxidation leads to an accumulation of G6P. This metabolite activates mTORC1 through unknown mechanisms, resulting in increased protein synthesis and ER stress. As a consequence, the heart hypertrophies (increased protein synthesis) and fails (contractile dysfunction induced by ER stress). Metformin and rapamycin decrease mTOR activity and may thus prevent LVH and HF. HK = Hexokinase-II. 219 cose uptake and preventing G6P accumulation. Treatment with metformin couples the rate of glucose uptake and oxidation and restores cardiac power in pressureoverloaded hearts. It is tempting to speculate that metformin could be a novel attractive adjunct treatment in patients with hypertension-induced LVH for the prevention of contractile dysfunction. Evidence for the beneficial use of metformin to treat diabetic patients with cardiac failure has recently been reviewed elsewhere [48] .
In conclusion, we have developed a new application of FDG PET as a tool to identify myocardial metabolic changes that precede irreversible structural changes of the left ventricle. This method will be of use to stratify the risk of hypertensive patients for developing HF.
